| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S82525-1mg买3赠1 |
99.00% | ￥250.00 |
9 | - | - | - | - |
|
S82525-5mg买3赠1 |
99.00% | ￥410.00 |
6 | - | - | - | - |
|
S82525-10mg促销 |
99.00% | ￥670.00 ￥536.00 |
5 | - | - | - | - |
|
S82525-25mg促销 |
99.00% | ￥1570.00 ￥1250.00 |
3 | - | - | - | - |
|
S82525-50mg促销 |
≥99% | ￥2700.00 ￥2160.00 |
货期：2-3天 | - | - | - | - |
|
S82525-100mg促销 |
≥99% | ￥4900.00 ￥3920.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | ABT-639 is a potent and selective T-type calcium channel blocker. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Calcium Channel;CalciumChannel | ||||||||||||||||||||
| 体外研究： | ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50 > 30 μM). ABT-639 has high oral bioavailability (%F = 73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents. | ||||||||||||||||||||
| 体内研究： | Following oral administration ABT-639 produces dose-dependent antinociception in a rat model of knee joint pain (ED50 = 2 mg/kg, p.o.). ABT-639 (10-100 mg/kg, p.o.) also increases tactile allodynia thresholds in multiple models of neuropathic pain. The antinociceptive profile of ABT-639 provides novel insights into the role of peripheral T-type (Cav3.2) channels in chronic pain states. | ||||||||||||||||||||
| 参考文献： | 1. Jarvis MF, et al. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem Pharmacol. 2014 Jun 15;89(4):536-44. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
